GCG and type 2 diabetes mellitus: GLP-1 receptor agonists' treatment reduces intrahepatic lipid content, induces a small weight loss, and improves glucose tolerance in individuals with T2D [34, 35], following RYGB and SG GLP-1 levels that increased similarly, thereby enhancing the beneficial effects of caloric restriction on the liver [10].